|
August
2002 (v02-n08) |
|
- Main Story
- pgs. 1-12 Market for Psychiatric Medications
- Macro Market Commentary
- pgs. 13-14
- NIBM Model Portfolio Updates
- pgs. 15-21
- Recommended Readings
- pg. 22-23
- NIBM Model Portfolio
- pg. 24
|
 |
|
| This month's Main Story
reviews the market for psychiatric medications. This sector is one of
the largest areas of drug sales and is growing rapidly as medicating
moods becomes more popular. In part one of a multi-issue discussion, we
focus on anti-psychotics for the treatment of schizophrenia and drugs
used to treat bipolar disorder. We will focus on major depression and
anxiety disorders in a subsequent publication. |
 |
|
| The following is an outline
of this issue of the NIBM Newsletter. |
Subscriber direct access |
|
| |
|
|
- Main Story - The market for Psychiatric
Medications
- Introduction
- Table: Major mental illnesses
- Why so little progress?
- Neurotransmitter disease model
- Nature vs. Nurture: Gene expression
and mental illness
- Evaluating competing drugs
-
- Schizophrenia
- Table: Schizophrenia symptoms
- Causes and treatments
- Table: Competitive landscape for
leading antipsychotics
- Neuroleptics
- Table: Neuroleptics
- Atypical antipsychotics
- Table: Atypical Antipsychotics
- Current Practice
- Milestones to watch
- Table: Selected drugs in
development
- Bipolar Disorder
- Table: Competitive landscape for
leading bipolar disorder drugs
- Lithium
- Valproate
- Other anticonvulsants
- Other drugs
Conclusion
Macro Market Commentary
- NIBM Model Portfolio and Updates
- Alliance Pharmaceutical
- Indevus
- Targeted Genetics
- Dendreon
- Seattle Genetics
- ID Biomedical
- Interesting Charts
- Alteon
- ID Biomedical
- Indevus
- Dendreon
Recommended Readings |
|
|
| |
|
|
 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
